1952 — Everest Medicines Cashflow Statement
0.000.00%
- HK$14.57bn
- HK$13.48bn
- CNY706.68m
Annual cashflow statement for Everest Medicines, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -5,658 | -1,009 | -247 | -844 | -1,041 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 5,088 | 184 | -951 | 66.5 | 354 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 77.9 | 63.2 | -0.323 | -68 | -126 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -472 | -730 | -1,156 | -769 | -680 |
Capital Expenditures | -520 | -976 | -433 | -266 | -204 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0 | — | -595 | 1,018 | 1,179 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Sale of Intangible Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -520 | -976 | -1,028 | 752 | 974 |
Financing Cash Flow Items | 0 | — | — | -7.95 | -19.7 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 5,638 | -76.5 | -25.3 | 10.1 | 37.8 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 4,375 | -1,841 | -2,149 | 32.3 | 361 |